Women's views, adherence and experience with postnatal thromboprophylaxis by Guimicheva, Boriana et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.thromres.2018.11.020
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Guimicheva, B., Patel, J. P., Roberts, L. N., Subramanian, D., & Arya, R. (2018). Women's views, adherence
and experience with postnatal thromboprophylaxis. Thrombosis Research.
https://doi.org/10.1016/j.thromres.2018.11.020
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
Accepted Manuscript
Women's views, adherence and experience with postnatal
thromboprophylaxis
Boriana Guimicheva, Jignesh P. Patel, Lara N. Roberts, Devi
Subramanian, Roopen Arya
PII: S0049-3848(18)30614-5
DOI: https://doi.org/10.1016/j.thromres.2018.11.020
Reference: TR 7211
To appear in: Thrombosis Research
Received date: 18 July 2018
Revised date: 17 November 2018
Accepted date: 19 November 2018
Please cite this article as: Boriana Guimicheva, Jignesh P. Patel, Lara N. Roberts, Devi
Subramanian, Roopen Arya , Women's views, adherence and experience with postnatal
thromboprophylaxis. Tr (2018), https://doi.org/10.1016/j.thromres.2018.11.020
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
1 
 
Women’s views, adherence and experience with postnatal 
thromboprophylaxis 
 
 
Boriana Guimicheva*¶, Jignesh P. Patel*†, Lara N. Roberts*, Devi Subramanian¶, Roopen 
Arya* 
 
 
*Department of Haematological Medicine, King’s Thrombosis Centre, King’s College Hospital 
Foundation NHS Trust, UK 
¶Department of Women’s Health, King’s College Hospital Foundation NHS Trust, UK 
†Institute of Pharmaceutical Science, King’s College London, UK 
 
 
Author for correspondence: 
Dr Jignesh P. Patel 
Institute of Pharmaceutical Science 
King’s College London 
London 
SE1 9NH 
Email: jig.patel@kcl.ac.uk 
Tel:  020 3299 2828 
Fax: 020 3299 4689 
 
 
Keywords: Adherence, Anti-embolic stockings, Experience, Intermittent pneumatic compression, 
Postpartum, Thromboprophylaxis, Views, Venous Thromboembolism 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
2 
 
Abstract 
Introduction 
Based on current guidelines, many women qualify for postnatal thromboprophylaxis following childbirth, 
however, little information exists on how adherent women are and their experiences to both 
pharmacological and mechanical forms of thromboprophylaxis. 
Materials and Methods 
Women requiring postnatal thromboprophylaxis were given questionnaire packs exploring their beliefs 
about enoxaparin, anti-embolic stockings (AES) and intermittent pneumatic compression devices 
(IPCD). Women were also asked to complete a diary recording when doses of enoxaparin were injected, 
along with an estimation of the number of hours the AES were worn each day, if at all. Results were 
entered onto SPSS and analysed. 
Results 
Sixty-seven women completed the questionnaire packs. Adherence to enoxaparin therapy was 
relatively high (82.4%). Women self-reported sub-optimal adherence levels to the AES, with 24% stating 
they never wore them once home. Reasons for this included being mobile, feeling hot and feeling as if 
they were cutting circulation off in the legs. Women reported a high level of acceptance of IPCD post 
caesarean section and would be happy for IPCD to be applied again in future deliveries, if required. 
Conclusions 
Although many women are adherent to postnatal TP, our findings suggest that adherence to AES is 
sub-optimal following discharge from hospital and therefore their usefulness is questionable. Front-line 
clinical staff should discuss the importance of adherence to postnatal TP, in order to avert preventable 
venous thromboembolic events.  
 
 
 
 
 
 
 
Highlights 
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 Adherence to postnatal thromboprophylaxis has been reported to be variable 
 Women’s adherence to mechanical and pharmacological thromboprophylaxis was explored 
 Adherence to enoxaparin therapy was relatively high (82.4%).  
 Adherence to stockings was low, with 24% of women stating they never wore them once 
home 
 Counsel women on the important role of thromboprophylaxis in preventing VTE 
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Introduction 
The gravid state and the postpartum period is known to increase the risk of venous thromboembolism 
(VTE). It is estimated that the relative risk of VTE increases by 5-fold during pregnancy, rising to as 
much as 60-fold during the puerperium [1]. Guidelines from America, Australia and New Zealand, 
Canada, Sweden and the United Kingdom all recommend risk assessment of women and prescribing 
of appropriate thromboprophylaxis (TP) in women identified at risk during this period [2-6], although 
they make differing recommendations on who should receive thromboprophylaxis postpartum. 
Clinicians charged with providing care for women during the postpartum period have to balance the risk 
of bleeding with that of thrombosis, when considering low molecular weight heparin (LMWH) therapy, 
with real consideration for the use of mechanical forms of TP (anti-embolic stockings (AES) or 
intermittent pneumatic compression devices (IPCD)) complementing pharmacological TP or when 
pharmacological TP is contra-indicated. 
The current Royal College of Obstetricians and Gynaecologists (RCOG) guidelines for the prevention 
of postpartum VTE suggests a score-based system in deciding which women should be prescribed 
postnatal TP and for how long [4]. Although there has been recent debate about the role of TP in this 
population and whether we are over thromboprophylaxing patients [7-9], particularly in light of the 
updated RCOG guidelines in 2015, our own work at King’s suggests that the number of women 
qualifying for postnatal TP is similar using the criteria from RCOG 2009 and 2015 [10]. 
When considering the different forms of TP offered to women, they might be considered cumbersome 
from the patient perspective; LMWH due to its parenteral nature, AES due to perceived discomfort and 
IPCD due to the restriction it imposes on mobility. Little information has been published in the literature 
on what women’s views and experiences of postnatal thromboprophylaxis are and whether they actually 
adhere to what is recommended to them, particularly once discharged from hospital. The reports that 
do exist, suggest that adherence to postnatal TP is variable [11-12].  Indeed, Patel and colleagues work 
suggests in comparison to the antenatal period, postnatal adherence to LMWH is sub-optimal in some 
women, possibly due to their routine being disrupted by the new-born, and a perceived decrease in 
necessity, relative to the antenatal period [11]. 
The aim of this study was to explore women’s views, experiences and adherence to postnatal 
thromboprophylaxis. 
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Materials and methods 
Study setting and recruitment 
This study saw collaboration between the departments of haematology and women’s health at King’s 
College Hospital (KCH). KCH is a 1000 bedded London teaching hospital based in South East London, 
providing tertiary care for cardiology, neurology, haematology and liver specialities. The hospital is 
densely populated inner-city area with  a skew in the population towards lower socioeconomic
 status. The women’s health department has approximately 5000 deliveries per annum.  The 
study was part of a larger parent study, evaluating the impact of mode of delivery and 
thromboprophylaxis on rotational thromboelastometry and thrombin generation in women with 
postpartum risk factors for VTE (paper under review). Women who took part in the parent study, were 
also invited to take part in this study. 
Participants 
Pregnant women were recruited from antenatal clinics where there was a clear indication for postnatal 
thromboprophylaxis, from pre-assessment clinics prior to planned caesarean section and, women 
admitted to the labour ward. The inclusion criteria were women aged over 18 years with planned 
hospital delivery. Exclusion criteria were inability to provide informed consent, antenatal 
thromboprophylaxis or long-term anticoagulation, inability to return to follow-up, non-local residence, no 
indication for postpartum thromboprophylaxis or a contraindication to LMWH, AES or IPCD.  
Women were prescribed weight-based enoxaparin thromboprophylaxis on the basis of their postpartum 
VTE risk assessment for 7 days or 6 weeks. VTE risk assessment was based on the RCOG guidelines 
for VTE prophylaxis [13]. Women delivering by caesarean section (CS) had IPCD (Covidien, 
Hampshire, UK) applied whilst in theatre and until mobile on the ward, in addition to thigh length AES 
(Covidien, Hampshire, UK). AES were provided to all women at high risk of VTE to continue for the 
same duration as enoxaparin based on VTE risk assessment. Following delivery, and prior to hospital 
discharge all participants were given a questionnaire pack, depending on if they had a vaginal delivery 
(VD) (questionnaires 1 and 2) or a CS (questionnaires 1, 2 and 3). Questionnaire 1 was based on the 
beliefs about medication questionnaire (BMQ) [14], exploring women’s beliefs on enoxaparin and AES, 
questionnaire 2 explored women’s experiences and views on the use of AES and their understanding 
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of VTE; and questionnaire 3 explored women’s experience of IPCDs (see online supplementary 
information 2-4 for copies of the questionnaires). 
The BMQ was chosen as it assesses beliefs regarding medication on 4 subscales; general harm and 
general overuse explore beliefs surrounding medication in general. Specific necessity determines the 
extent the patient recognises the need for a specific therapy, while the specific concern subscale 
determines how strong their anxieties towards a specific therapy are (in this case being enoxaparin and 
then adapted to assess AES).  Subscales for general harm and overuse (based on 4 items each) could 
have a minimum score of 4 and a maximum score of 20. Scales for specific necessity and concerns 
could have a minimum score of 5 and a maximum score of 25. Internal consistency of the subscales 
for questionnaire 1 was evaluated using Cronbach alpha. The Cronbach alpha for enoxaparin for the 
general harm subscale was 0.7, for general overuse it was 0.8, and for the necessity and concerns 
subscales were both 0.7. The Cronbach’s alpha for the necessity and concerns subscales for AES were 
0.8 and 0.7, respectively. All sub-scales demonstrated reliable internal consistency [15]. The BMQ was 
considered an appropriate tool to utilise for this study, as it has previously been used in the gravid 
setting with enoxaparin, exploring whether women’s beliefs relate to their adherence to  enoxaparin 
[11]. For interested readers, other examples of how the BMQ has previously been used to explore the 
relationship between beliefs and medication adherence are listed here [16-17]. 
Women were asked to return the completed questionnaire pack at one of their follow up appointments, 
and were reminded to bring completed questionnaires back by phone prior to their follow-up 
appointments. 
Additionally, all participants were given a diary to record the exact dates and times they took their 
enoxaparin injections, as well as their use of AES, including an estimate of number of hours worn each 
day. This diary was returned at the same time as the questionnaire pack, at a follow-up appointment, 
once TP had ceased at either day 7 postpartum or day 42 postpartum. Participants were assured that 
their responses would not be made available to their treating physician or midwife.  
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Analysis 
Data from the questionnaires was coded and entered into SPSS (version 23, IBM SPSS, Chicago, IL, 
USA). Continuous variables are given as means and standard deviations (SD) or median and 
interquartile range (IQR) for normal and non-normal data, respectively. 
For questionnaire 1, sub-scale scores for overuse, harm, necessity and concerns were calculated, as 
outlined previously. Differences in subscale scores between the mode of delivery, length of TP 
prescribed and ethnicity were investigated. Furthermore, a necessity-concerns differential was 
calculated [18] for the cohort, and then separately for the subgroups and compared. This differential 
calculates the difference between the patients’ perceived necessity for treatment and their concerns, 
with a positive differential score associated with the patients’ intention to adhere to treatment.  
Fisher’s exact test was employed to compare nominal data between groups. 
For questionnaires 2 and 3, percentage agreement (when participants responded ‘agree’ or ‘strongly 
agree’) with each statement are presented.  
For the purposes of analysis, non-adherence to pharmacological prophylaxis was defined as >1 dose 
of enoxaparin missed. 
Ethical approval 
The study was approved by the London Riverside Research Ethics Committee and King’s College 
Hospital NHS Foundation Trust Research and Development department. All participants provided 
informed written consent prior to data collection. 
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Results 
Ninety-nine participants consented to take part in the parent study and were given diaries and the 
questionnaire pack to complete, of which 67 women completed questionnaire 1 (68% response rate), 
45 women completed questionnaire 2 (45% response rate) and 30 women completed questionnaire 3 
(69% response rate). Supplementary table 1 described the details of the 99 women who took part in 
the larger parent study. Table 1 outlines the details of the 67 women who returned questionnaire 1. The 
women who returned completed questionnaires mirror the women who took part in the parent study. 
Table 1: Characteristics of the 67 women who completed questionnaire 1 
Characteristic  
Mean age (SD) 36.2 (4.4) 
Mode of delivery, n (%) 
Vaginal 
Caesarean Section 
 
21 (31.3) 
46 (68.7) 
Ethnicity, n (%) 
Caucasian 
African-Caribbean 
Other 
 
49 (73.1) 
16 (23.9) 
2 (3.0) 
Mean BMI, kg/m2 (SD) 28.5 (7.0) 
Median postpartum risk factors, n (IQR) 3 (2-4) 
Planned enoxaparin duration, n (%) 
7 days 
6 weeks 
 
50 (74.6) 
17 (25.4) 
SD Standard deviation, IQR Interquartile range 
 
 
Self-reported adherence to enoxaparin and AES 
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Fifty-one women returned completed diaries of self-reported adherence to enoxaparin and AES. The 
number of women reporting no more than 1 missed dose was 82.4%. When split into duration of 
enoxaparin (7 days or 6 weeks), the adherence dropped to under half with the longer duration of 
treatment, with more missed doses, though not significantly different (p=0.1).  
The documented self-administration dates and times were reviewed in the diaries and 40% did not take 
the enoxaparin within 2 hours of the prescribed time. Additionally, participants had been asked to 
document the site of enoxaparin injections with 96% of doses self-administered the injections in the 
trunk region. 
In relation to wearing the AES as directed (same duration as the LMWH), 69% of respondents wore the 
stockings up to day 5 at home, with only 32% wearing them for more than 12 hours a day, and 24% not 
wearing them at all post discharge. 
 
Women’s beliefs about the enoxaparin 
Of the 67 completed questionnaires returned, 46 were from women in the CS delivery group and 21 
from VD group. The women’s responses to the four sub-scales within the BMQ are outlined in table 2. 
In general, the perception of harm and overuse appeared to be low in this group.  
There were no differences found when comparing the total harm and overuse sub-scale scores with 
mode of delivery, duration of thromboprophylaxis, or ethnicity (data not shown). 
 
 
 
 
 
 
Table 2: BMQ Enoxaparin 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
10 
 
Subscale Mean (SD) VD Mean 
(SD) 
CS Mean 
(SD) 
7-day  
enoxaparin 
6-week 
enoxaparin 
Total Harm 7.5 (2.4) 7.8 (2.5) 7.3 (2.4) 7.3 (2.5) 7.9 (2.2) 
Total Overuse 9.8 (3.6) 10.6 (3.2) 9.4 (3.7) 9.3 (3.5) 11.0 (3.8) 
Total Necessity 11.5 (2.9) 11.5 (2.3) 11.5 (3.2) 11.2 (3.1) 12.4 (2.3) 
Total Concerns 10.3 (3.1) 10.5 (3.1) 10.3 (3.2) 9.9 (2.9) 11.7 (3.5) 
Necessity-Concerns 
Differential 
1.18 1 1.2 1.3 0.7 
Means and standard deviations (SD) for each subscale, and by mode of delivery (VD- vaginal delivery; CS- caesarean 
section), and length of enoxaparin thromboprophylaxis prescribed 
The Necessity-Concerns Differential (NCD) was found to be 1.18 for the cohort as a whole, with the 
positive differential suggesting that the participants feeling that the necessity of the enoxaparin was 
greater than any concerns they may have held and an intention to adhere to the enoxaparin.  
When comparing mode of delivery and ethnicity sub-groups there were no differences found. However, 
when the NCD was calculated for each sub-group, VD had a lower NCD (1) compared to CS (1.2).  
Participants were prescribed either 7 days or 6 weeks of postpartum thromboprophylaxis of enoxaparin 
and AES, depending on their VTE risk. Most of the participants were prescribed a 7-day course of 
enoxaparin and AES (76%). When comparing total necessity and concerns between these two groups, 
there were no differences in necessity scores. However, total concerns were higher in the 6-week 
enoxaparin group (mean [SD] of 11.7 [3.5] vs 7 days enoxaparin group 9.9 [2.9]; p=0.042). 
The women who had a six-week long course of enoxaparin prescribed also had a lower NCD (0.7) than 
the women prescribed the shorter 7-day course (1.3) (Table 2). 
When the self-reported diary cards were used to group participants adherence into (1) fully adherent, 
or (2) with more than 1 dose missed, there were no significant differences between the groups, and 
only a slightly higher NCD in the fully adherent group (see table 3). 
 
Table 3: Fully adherent and sub-optimal adherent groups' total necessity and concerns, and NCDs 
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Adherence  Total Necessity 
Mean (SD) 
Total Concerns  
Mean (SD) 
NCD 
Complete 11.6 (3) 10 (2.8) 1.6 
>1 dose missed 12.9 (2) 11.6 (1.8) 1.3 
 
Women’s beliefs surrounding the AES 
Table 4 outlines the perceived necessity and concerns of wearing the AES. For stockings, the NCD 
value was 2.7, higher than for enoxaparin. When comparing each subscale by mode of delivery, length 
of thromboprophylaxis and ethnicity, no significant differences found. However, the NCD of women who 
delivered by caesarean was higher (3) as compared to the vaginal delivery group (2.1). Similarly, the 
women who we asked to wear stockings for 7 days appeared to have a higher necessity-concerns 
differential (2.9), compared to those who were asked to wear them for 6 weeks (2), mirroring what was 
found with enoxaparin. 
Table 4: BMQ results of AES 
Subscale Mean (SD) VD Mean 
(SD) 
CS Mean 
(SD) 
7-days of  
AES 
6-week of 
AES 
Total Necessity 12.3 (3.9) 11.6 (3.5) 12.6 (4.1) 12 (4) 13 (3.7) 
Total Concerns 9.6 (3.3) 9.5 (3.3) 9.6 (3.2) 9.1 (3.1) 11 (3.5) 
Necessity/Concerns 
Differential 
2.7 2.1 3 2.9 2 
Means and standard deviations (SD) for each subscale, and by mode of delivery (VD- vaginal delivery; CS- caesarean 
section), and length of mechanical thromboprophylaxis prescribed 
 
Women’s experiences of wearing AES following childbirth  
Questionnaire 2 explored participants views and experiences of AES and to their beliefs in relation to 
the impact a DVT or PE might have on their health.  
The first section of the questionnaire enquired as to the adherence to wearing the stockings, with only 
30% of respondents wearing the AES as directed on a daily basis, 18% wearing them most days, 27% 
wearing them less than instructed and a quarter of respondents not wearing them at all after discharge. 
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The second section explored the reasons why participants may have worn the stockings other than as 
instructed. Table 5 gives percentages agreement of responses. 
Most of the participants indicated that they knew the function of the AES. In terms of adverse 
experiences, 40.9% agreed indicating agree or strongly agree that the AES felt as though they were 
cutting off the circulation in their legs, 53% felt they were too hot, 37.2% agreed they did not look nice 
and 35.6% found them itchy. Only 20% agreed that the AES made their legs sore, with just 4.7% 
experiencing a rash, and 23.3% agreed that they were difficult to put on. Over 66% felt that as they 
were active and mobile they did not need to wear the stockings. 
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Table 5: Participants reasons for not wearing AES 
Statement % Agreement 
n=45 
I was active and mobile and therefore did not need them 66.7 
I found the stockings too ‘hot’ to wear 53.4 
The stockings felt as though they were cutting off the ‘circulation’ in my legs 40.9 
The stockings kept ‘falling down’ 38.7 
The stockings did not look nice 37.2 
I found the stockings ‘itchy’ on my skin 35.6 
I was unable to put the stockings on 33.3 
The stockings caused my legs to feel sore 20 
The stockings were not prescribed by a doctor; therefore, I did not think it was 
important to wear them 
7 
I was not sure what the purpose of the stockings were 7 
The stockings caused a rash on my skin 4.7 
There is no particular reason why I did not wear the stockings 4.7 
 
The last section of questionnaire 2 explored perceptions to the seriousness and impact of a potential 
DVT or PE (table 6). Almost all, 98.4% agreed that DVT, and 96.9% that PE are serious medical 
conditions. In relation to the impact a DVT & PE would have, 90.7% agreed that it would impact their 
ability to care for their baby and 87.5% agreed it would impact their daily activities. 
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Table 6: Participants perceptions of DVT and PE 
Statement % Agreement 
n=45 
DVT is a serious medical condition 98.4 
PE is a serious medical condition 96.9 
A DVT or a PE would have a negative impact on my ability to look after my baby 90.7 
A DVT or a PE would have a negative impact on my ability to complete daily activities 87.5 
A DVT or a PE would have a negative impact on my ability to work 83.9 
A DVT or a PE would have a negative impact on my ability to engage in social activities 82.5 
 
Women’s experiences of the intermittent pneumatic compression devices  
The women who delivered by caesarean section had an additional questionnaire administered. This 
aimed to explore their experiences using the IPCD, applied before the onset of surgery and kept on 
until either transfer to the postnatal ward or until the effects of the spinal anaesthesia had worn off. The 
median time the IPCDs were used was 311 minutes IQR (210-563).  
Table 7 summarises the responses. The majority of these appeared to be positive, suggesting that the 
IPCD are well tolerated by this group of patients. Items such as the IPCD’s loudness and keeping mum 
and baby awake were disagreed with by 73.3%, 76.6% and 93.3% respectively. They were found to be 
comfortable by 86.7%, with only about a third of women feeling that they restricted mobility and none 
of the respondents finding them painful. 
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Table 7: Patients’ experiences of using the IPCD 
Experiences using the foot pump (IPCD) following the birth of your baby % Agreement 
n=30 
The foot pump felt comfortable when applied to my legs 86.7 
If I have another baby and need to have another caesarean section, I would be 
prepared to apply the foot pumps again 
86.7 
I found the foot pumps soothing when applied to my legs 60 
I was happy to apply the foot pumps all the time (day and night) 53.6 
I preferred to use the foot pumps whilst I was in bed 46.7 
The foot pumps restricted my mobility 36.3 
The foot pumps were loud 20 
The foot pumps made my legs sweat 16.7 
The foot pumps kept me awake 16.6 
I preferred to apply the foot pumps only during the day 15.3 
I preferred to apply the foot pumps only during the night 10.7 
I preferred to use the foot pumps whilst I was sitting in my chair 10 
The foot pumps felt hot when applied to my legs 9.7 
The foot pumps kept the baby awake 3.3 
I found the foot pumps painful when applied to my legs 0 
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Discussion 
Our study evaluated women’s beliefs, experiences and adherence to postnatal TP. We found a 
relatively high self-reported adherence rate to pharmacological TP (82.4%). This is in line with 
previously reported studies in this population group [11-12] and suggests that when women are 
prescribed parenteral pharmacological TP, largely, they will adhere. In Patel and colleagues study, 
postnatal adherence to enoxaparin was reported at 93%, where the same women had also been 
prescribed antenatal TP [11]. In Horden and colleagues study of women prescribed just postnatal TP 
[12], adherence to the full course was reported at 83%. Interestingly, when we analysed adherence by 
duration of prescription, the women prescribed 6 weeks of postnatal enoxaparin were less adherent at 
57% compared to 86% for the 7 day course (although not statistically significant). However it must be 
borne in mind that our definition of non-adherence was defined as 1 or more doses missed. Therefore, 
the potential for missing doses was greater in the 6 week group. In our study, we did not collect reasons 
for why doses of enoxaparin were missed. Common reasons reported in Horden’s study for omission 
of doses or not completing the course of TP were bruising or wound complications, forgetting, a fear or 
dislike of needles and feeling that the injections were not helping [12]. 
Our analysis of the results from the enoxaparin specific section of the BMQ suggest, that women 
appeared to be accepting of the need to take enoxaparin (positive necessity-concerns differential value 
of 1.18). We found no difference between perceived necessities and concerns in relation to mode of 
delivery or ethnicity. Horden and colleagues have also reported that women are highly accepting of 
postnatal TP [12]. In their study, 94.5% of women questioned indicated that they would accept TP in a 
future pregnancy. 
Previously published research has concluded that women’s perceptions of medicine can be augmented 
by pregnancy, with higher or exaggerated concerns in relation to the effect a medication may have on 
their baby [19]. In our study, we found that 74.7% of women agreed that whilst they were breastfeeding 
they place a higher priority on the impact any medicine that they may be taking will have on their baby 
than to beneficial effects the medicine may have on them. This suggest that the breastfeeding women 
may experience an extension of concerns held antenatally and is an important reminder to front-line 
staff to counsel women on the safety of LMWH when women breastfeed. 
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In Patel’s study [11] it was reported that compared to antenatal period, postnatal adherence dropped in 
a number of women and they suggest that women’s routine could be upset during the immediate 
postnatal period, due to the early challenges of motherhood. When the returned diary cards were 
examined in our study, we found many women (40%), not taking their daily dose within 2 hours of the 
previous day, suggesting this to be a factor.  
There is a scarcity of information in the literature, on the the potential effect of missed doses or delayed 
doses of LMWH TP has on outcomes in terms of VTE rates. In a surgical and trauma inpatient setting, 
Louis and colleagues [20] found that 59% of their study cohort missed at least 1 dose of LMWH. The 
authors reported a 4.8% DVT rate in the uninterrupted therapy group, and a 23.5% DVT rate in the 
interrupted therapy group (p < 0.01). This study was run on an inpatient population, and adherence was 
not primarily influenced by patient decisions, furthermore, they included asymptomatic DVTs in their 
event rate. However, the findings suggest non-adherence as a possible cause for TP failure. Measuring 
VTE rates was outside the scope of our study, although no participant developed VTE while taking part; 
however, lengthier follow up in future research in this area would be beneficial. 
Guideline writers and those providing care for women postnatally need to consider findings such as 
these, as if adherence is poor for women prescribed 6 weeks of LMWH, strategies aimed at patient 
support should be explored, particularly as the women questioned seemed to have a good 
understanding of what DVT and PE is and the impact it could have on them and their abilities for 
providing child-care during the first few weeks post-delivery. 
Bates and colleagues have completed work exploring women’s values and preferences for 
thromboprophylaxis during pregnancy [21]. To the best of our knowledge, no similar work exists in the 
postnatal population. This perhaps is unsurprising, given the higher number of women who would be 
eligible to TP postpartum, however, given the uncertainty and debate surrounding who warrants TP [7-
9], it would be interesting to illicit women’s views in the postnatal setting on this. This may well help 
future guideline panels in the recommendations they make.  
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Women’s adherence and experiences of using AES 
Women’s adherence to AES was relatively low compared to pharmacological TP, even though many 
women (96%) agreed that a DVT or a PE is a serious medical condition, and 91% of women returning 
the questionnaire agreeing that a DVT or a PE would impact on their ability to care for their infant. One-
third of women reported not wearing the AES once at home. Interestingly, the necessity-concerns 
differential for AES was 2.7; higher than that reported for enoxaparin. This raises questions as to why 
women were then so non-adherent with AES, despite a strong understanding and necessity for them. 
Over 50% of women reported that the stockings made them feel too hot, 41% identified with the 
stockings feeling too tight, and 39% had experienced them falling down suggesting that the sizing of 
the stockings patients were given may have been inappropriate. All of these factors require greater 
attention, before patients are discharged home. Of the 7 women prescribed 6 weeks TP with enoxaparin 
and AES who returned the questionnaires and diaries, only 2 reported wearing the stockings past 23 
days. This may be related to a perception that they had returned to normal levels of mobility, and thus 
they were not required.  
The reasons for non-adherence given by women resonate with the findings from Gray and Ash [22], 
who surveyed pregnant women’s use of AES on an antenatal ward, with no advice received and 
discomfort, as the 2 reasons commonly cited by the 38% of women who were non-wearers. Although 
their setting was the antenatal setting, the discomfort reason certainly chimes with our findings. Comfort 
and ease of use have also been cited as important by patients asked to wear compression stockings 
chronically in the setting venous leg ulcers [23-24]. 
Recently published guidance from the National Institute for Care Excellence (NICE) suggests combined 
TP with LMWH plus mechanical prophylaxis, for women who have given birth or had a miscarriage or 
termination of pregnancy in the past 6 weeks and who are likely to be immobilised, or have significantly 
reduced mobility relative to their normal or anticipated mobility for 3 or more days after surgery, including 
caesarean section. With respect to mechanical prophylaxis, NICE suggests using IPCD as first-line 
treatment and if IPCD is contraindicated, to use AES. They also state, that this should continue until 
the woman no longer has significantly reduced mobility relative to her normal or anticipated mobility or 
until discharge from hospital [25]. Given the high levels of non-adherence reported by women to AES 
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and the recently published NICE guidance, the role of AES should perhaps be reviewed by maternity 
units. 
Women’s experiences of the IPCD 
The questionnaire regarding IPCDs suggested that they are generally well tolerated, with very few 
complaints of them being loud or hot, most respondents agreeing that they were comfortable and 60% 
agreeing that they found them soothing, suggesting a high degree of acceptability to women. When 
asked if they would use them at their next delivery if warranted, 86.7% agreed that they would. This is 
encouraging, although during the execution of this study, it was observed that not all staff were 
competent in their application and if this is representative, then maternity units should ensure this is 
improved. It must be remembered, that the time CS women had to apply the IPCD was short and if 
IPCD replace AES as a principal form of compression TP in the future, then work around their 
acceptability for longer periods of time is required.  In Palmero and colleagues cross-sectional study of 
adherence to ICPD in 293 women, 21% of women were non-compliant with SCD use [26]. Reasons for 
this noncompliance included patient discomfort, machine malfunction and incorrect device use. Others 
on the other hand have also reported high levels of patient acceptance of foot pump devices as TP in 
the orthopaedic surgery setting [27-29].  
Limitations 
Our work is limited by the fact, that not all women who took part in the parent study, returned completed 
questionnaires. The response rate for questionnaire 1 was high and in line with other questionnaire-
based studies, however, the responses rates for questionnaires 2 was lower. Our findings however 
resonate with previously published findings. The adherence rates and responses to questionnaires 
reported in our study were self-reported, so its impossible to exclude the fact that some women may 
have given socially acceptable answers and an over-estimation of their adherence. We also found that 
women’s knowledge of DVT and PE was good. Its difficult to know whether this was acquired knowledge 
by their participation in this study or not and so a degree of mindfulness is required when interpreting 
the high knowledge levels reported. 
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Conclusion 
Our study found that women had a good understanding of what DVT and PE was and thus their 
adherence to LMWH postnatally was relatively good. Post discharge adherence to AES was not as 
good as LMWH and their specific role is questionable in this setting, particularly in light of recent NICE 
guidance. Front line staff working on maternity units should ensure women are given clear advice and 
instructions on how long and why TP should be used and the role it plays in VTE prevention. Future 
work should focus on the role non-adherence has on outcomes in this setting.
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Supplementary online information 
Supplementary table 1 Baseline characteristics of the women who took part in the larger parent study 
Characteristic Whole 
Cohort 
Vaginal 
Deliveries 
Caesarean 
Sections 
P 
Mean age (SD) 35.8 (5.0) 36.5 (5.4) 36 (4.8) 0.3 
Mode of delivery, n (%) ----- 32 (32.3) 
 
67 (67.7) n/a 
Median duration of 
labour/surgery, min (IQR) 
 
75 (45-484) 363.5 (123-
585) 
54 (41-173) 0.001* 
Ethnicity, n (%) 
Caucasian 
African-Caribbean 
Other 
 
 
64 (64.6) 
33 (33.3) 
2 (2.1) 
 
19 (59.4) 
13 (40.6) 
0 
 
20 (29.9) 
13 (67.1) 
2 (3) 
 
 
0.38 
Mean BMI, kg/m2 (SD) 
 
29 (7.3) 31.2 (8.1) 27.9 (6.8) 0.04* 
Parity, pre-delivery, n (%) 
0 
1 
2 
≥3 
 
 
33 (33.3) 
30 (30.3) 
23 (23.2) 
13 (13.1) 
 
5 (15.6) 
8 (25) 
10 (31.3) 
9 (28.1) 
 
28 (41.8) 
22 (32.8) 
13 (19.4) 
4 (6) 
 
 
0.003* 
Assisted conception, n (%) 
Multiple pregnancy, n (%) 
Pre-eclampsia, n (%) 
Infection, n (%) 
 
11 (11.15) 
13 (13.1) 
35 (35.4) 
10 (10) 
3 (9.4) 
4 (12.5) 
11 (34.4) 
5 (15.6) 
8 (11.9) 
9 (13.4) 
24 (35.8) 
5 (7.5) 
0.70 
0.90 
0.89 
0.24 
Median postpartum risk 
factors, n (IQR) 
3 (2-4) 3 (2-3) 3 (2-4) 0.23 
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Breastfeeding at T4, n (%) 
 
75 (75.8) 
 
28 (87.5) 47 (70.1) 0.14 
Planned enoxaparin duration, 
n (%) 
7 days 
6 weeks 
 
 
 
75 (75.8) 
24 (24.2) 
 
 
 
20 (62.5) 
12 (37.5) 
 
 
 
55 (82.1) 
12 (17.9) 
 
 
 
0.045* 
 
SD, standard deviation; IQR, interquartile range; BMI, body mass index. Significance 
indicated (*) at the 0.05 level. 
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